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Background: Inappropriate implantable cardioverter-deﬁbrillator (ICD) shocks is a common complication
in Brugada syndrome. However, the incidence in recipients of ICD for primary and secondary prevention
is unknown.
Method and results: We compared the rate of inappropriate shocks in patients with Brugada syndrome
that had an ICD for primary and secondary prevention. We studied 51 patients, 86.5% of whom were
males. Their mean age at diagnosis was 47 ± 11 years. Eighteen (35%) were asymptomatic, while 25 (49%)
experienced syncope prior to implantation. Eight (16%) patients were resuscitated from ventricular
ﬁbrillation before implantation. During a mean follow-up of 78 ± 46 months, none of the asymptomatic
patients experienced appropriate therapy, whereas 21.6% of symptomatic patients had 1 shock. Inap-
propriate shock occurred in 7 (13.7%) patients, with a mean IS of 6.57 ± 6.94 shocks per patient occurring
16.14 ± 10.38 months after implantation. There was a trend towards higher incidence of inappropriate
shock in the asymptomatic group (p ¼ 0.09). The interval from implantation to inappropriate shock
occurrence was 13.91 ± 12.98 months. The risk of IS at 3 years was 13.7%, which eventually plateaued
over the time.
Conclusion: Inappropriate shock is common in Brugada syndrome during the early periods after an ICD
implantation, and seems to be more likely in asymptomatic patients. This ﬁnding may warrant a review
of the indications for ICD implantation, especially in the young and apparently healthy population of
patients with Brugada syndrome.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Brugada syndrome (BrS) is a life-threatening arrhythmogenic
disorder requiring implantation of cardioverter-deﬁbrillator (ICD)
in some patients to prevent sudden cardiac death (SCD) [1,2]. From
the discovery of the disease until recent years, ICD has been
implanted almost systematically in asymptomatic BrS carriers with
1 risk factors such as spontaneous type 1 ECG (Fig. 1), inducible
ventricular ﬁbrillation (VF) during programmed electricalrvice de cardiologie, 12 rue
Rhythm Society.
ociety. Production and hosting by
t al., Inappropriate implantab
acing and Electrophysiologystimulation (PES), and family history of premature death without
strong evidence of the rationale for this preventive approach.
Because of the low event rates observed on ICD-stored electro-
grams over a long period of follow-up after implantation, two
contending views with regard to appropriateness or otherwise of
primary prevention by ICD in BrS have emerged [3e10]. The aim of
our study was to compare the rates of inappropriate shock (IS) in
the setting of primary and secondary prevention in BrS recipients of
ICD.
2. Methods
2.1. Study population
Consecutive patients diagnosed with BrS who underwent ICDElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
le cardioverter-deﬁbrillator shocks in Brugada syndrome: Pattern in
Journal (2016), http://dx.doi.org/10.1016/j.ipej.2016.10.010
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and ICD therapy, whether appropriate shock (AS) or IS docu-
mented. The patients were divided into 2 categories of asymp-
tomatic (group A), and symptomatic (syncope or cardiac arrest,
group B) subjects prior to implantation. Diagnosis of BrS was made
based on an episode of aborted sudden cardiac arrest (SCA) or
during evaluation of syncope, occurrence of spontaneous ECG
pattern consistent with BrS in asymptomatice subjects undergoing
routine evaluation, or during screening of kindred of patient diag-
nosed with BrS. This registry was approved by institutional review
committees, and the subjects gave informed consent.2.2. Diagnosis, clinical data, and diagnostic workup
The following clinical data were collected in the participating
centers: circumstances and age at the time of diagnosis, gender,
family history of SCD before the age of 45 years, presence of atrial
ﬁbrillation (AF) and ventricular tachycardia (VT) before ICD im-
plantation, results of pharmacological testing for unmasking the
characteristic coved-type ECG pattern, results of invasive electro-
physiological study (EPS), and indication for ICD implantation.
Diagnosis of BrS was made in accordance with the recommen-
dations of the second consensus conference [11]. Patients had to
have a prominent coved-type ST-segment elevation (Fig. 1) dis-
playing J-wave amplitude or ST-segment elevation0.2 mV at its
peak, followed by a negative T wave [11]. In subjects with type 2 or
type 3 ECG pattern and other reasons for suspecting the BrS,1.0mg/
kg of ajmaline (a class I antiarrhythmic drug) was administered
intravenously at a rate of 10 mg per minute, and a 12-lead ECG
monitored for ST-segment changes of the coved-type BrS pattern.
Patients with a history of presumed arrhythmic syncope, docu-
mented sustained VT, or aborted SCA were considered
symptomatic.
We excluded conditions mimicking BrS by undertaking the
following investigations: laboratory tests to exclude acute cardiac
ischemia as well as metabolic and electrolyte disturbances; echo-
cardiography and stress testing where indicated; coronary and/or
right ventricular angiography, radionuclide ventriculography and
cardiac magnetic resonance imaging to rule out structural heartFig. 1. Diagnostic ECG pattern of Brugada syndrome. Spontaneous coved-type S-T eleva
Brugada syndrome.
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behest of an experienced electrophysiologist. Until 2010, ICD was
implanted in asymptomatic patients in whom sustained VF was
induced by any level of programmed stimulation.
2.3. ICD follow-up
In the absence of symptoms or device therapy, patients were
routinely seen for ICD interrogation every 3e6 months (depending
of physician's protocol). ICD programming consisted of a single
detection (VF) zone above 200 to 220 bpm. Appropriate therapies
were deﬁned as shocks or antitachycardia pacing delivered for VT
or VF. Inappropriate shock was deﬁned as shock delivered in the
absence of documented ventricular arrhythmias. We ﬁrst counted
overall occurrence of arrhythmic events (self-terminating ventric-
ular arrhythmias, anti-tachycardia pacing and appropriate shocks)
and IS. Afterwards, we compared event rates between both groups.
Quinidine hydrochloride (300 mg twice daily) was added for sup-
raventricular tachyarrhythmia or electrical storm during follow-up.
2.4. Statistical analysis
Continuous variables were expressed as the mean ± SD or the
median and interquartile range for non-normally distributed data.
Categorical variables were expressed in percentage and compared
using the Chi-square test while continuous variables were
compared using the Student's t-test. Conditions of validity of tests
were checked and in case they were not veriﬁed we performed
non-parametric tests (Fisher exact, andMann-Whitney). The event-
rate curve was determined using the Kaplan-Meier method. The
differences in the rate of appropriate therapy and IS-free survival
were analysed with the Log-rank test. To assess the contribution of
baseline patient characteristics to the prediction of the likelihood of
ﬁrst IS during follow-up, multivariable Cox proportional hazard
regression analysis was used. Adjustment variables were age at
diagnosis, the coved type ECG pattern, the history ofAF, and the
treatment with quinidine which was analysed in intention-to-treat
fashion. Given the low incidence and prevalence of BrS in the
general population [12], we assumed the choice of 10% a level fortion in right precordial leads (mostly in V1 and V2 rather than V3) is the hallmark of
ble cardioverter-deﬁbrillator shocks in Brugada syndrome: Pattern in
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Institute, Cary NC).
3. Results
3.1. Clinical characteristics and ICD indications
The study population characteristics are summarized in Table 1.
Fifty-one patients (male ¼ 86.5%) with a mean age at diagnosis of
47 ± 11 years (20e70 years) were studied. Three patients were lost
to follow-up at 13, 14 and 23months respectively. The vast majority
of patients were white (94%), with people of Asian and African
decent constituting 4% and 2% respectively. Spontaneous type 1
ECG pattern was found in 40 (78.4%) patients at baseline, whereas
11 (21.6%) were challenged with Ajmaline to unmask the coved
type ECG pattern. EPS was performed in 39 (76.5%) patients, 34
(88%) of whom had it before the FINGER publication [4]. Age at
diagnosis, gender, a spontaneous type 1 ECG, history of AF and/or
non-sustained VT, induced VF/polymorphic VT during EPS, SCN5A
gene mutation, and need for quidinine medication were similar in
symptomatic and asymptomatic individuals (Table 1).
Eighteen (35%) patients were asymptomatic at the time of
diagnosis, while 25 (49%) had previously had at least 1 episode of
syncope with no clear extracardiac cause. Eight (16%) patients had
been resuscitated from VF prior to diagnosis of BrS. Indication for
primary ICD prevention was based on the presence of a type 1 ECG
pattern (either spontaneous or induced by drug challenge) in
conjunction with (1) inducible ventricular arrhythmias (n ¼ 9),
and/or (2) a family history of SCD (n ¼ 9). A family history of SCD
was found in 21 (41%) patients. Atrial Fibrillation was diagnosed in
7 (13.7%) patients prior to ICD implantation. A single-chamber ICD
was implanted in all patients, but one was upgraded to dual-
chamber implant for inappropriate therapies due to AF. Implanta-
tion data (DFT, pacing threshold, and R-wave amplitude) were
available in all patients.
3.2. Outcomes
During a mean follow-up of 78 ± 46 months (median 76
months; range 1e192 months) after ICD implantation, 1 extra-
cardiac death due to haematological disorder occurred. Therapies
(either AS or IS) and ICD-related complications are listed in Table 2.
Asymptomatic patients were free from any life-threatening ar-
rhythmias as detected by ICD, and appropriate ICD shocks were
documented only in symptomatic patients.
Inappropriate therapies: IS occurred in 7 patients (13.7%; mean
6.57 ± 6.94 shocks per patient) after a mean follow-up of
16.14 ± 10.38 months from ICD implantation, reaching its peak of
13.7% at 3 years, where it remained over the ensuing 7 years
(Table 3).
Compared to symptomatic patients, asymptomatic BrS carriers
experienced IS more frequently (27.8% versus 6.1%, p ¼ 0.08,
Table 2). The freedom from IS tends to diverge between both groups
if we consider the risk a of 10% (p¼ 0.09, Fig. 2). Reasons for IS were
lead dysfunction (n¼ 4), supraventricular arrhythmias (n¼ 2), or T-
wave oversensing (n ¼ 1). One asymptomatic BrS carrier experi-
enced 10 IS for T wave oversensing. Another asymptomatic subject
experienced 17 IS due to a Sprint Fidelis (Medtronic, Mineapolis,
MN) lead failure (Fig. 3) implanted for near-syncope, and ajmaline-
induced type 1 ST-segment elevation.
Other complications: Pocket infection was diagnosed in 2 (3.9%),
and endocarditis in 1 (2%). Treatment for depression as a result of
frequent inappropriate shocks was reported in 1 (5.6%) asymp-
tomatic patient, while 1 (3%) symptomatic patient received anti-
depressants due to chronic pocket chest pain.Please cite this article in press as: Bonny A, et al., Inappropriate implantab
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4.1. Main ﬁndings
The results of this study shows a trend towards higher incidence
of IS in patients with BrS who did not experience syncope nor
cardiac arrest before ICD implantation, particularly during the ﬁrst
3 years of the device. The outcome of this cohort also conﬁrmed the
assertion regarding the usefulness of ICD in preventing sudden
death in patients with previous arrhythmic events [13], and that
asymptomatic BrS-carrier patients have a good long-term prog-
nosis [14].
4.2. Inappropriate shocks
Inappropriate shock is a common adverse effect occurring in
recipients of ICD, regardless of the underlying disease or indication
[15]. In asymptomatic BrS population with several risk factors for
sudden death, Sarkozy et al. [6] registered 17 IS in 47 patients after
47.5 months of ICD implantation. Sacher et al. [4] found the prev-
alence of 24% after 6 years with a risk at 10 years of 34%, a preva-
lence similar to that reported by Miyazaki et al. [13] 7 years of
follow-up. In a high-risk pediatric hypertrophic cardiomyopathy
cohort, Maron et al., found that ICD-related complications, partic-
ularly IS, occurred more commonly in asymptomatic patients than
recipients for secondary prevention [16]. This has not been studied
in the BrS population yet. Our data showed a trend towards higher
propensity for unnecessary therapies particularly in asymptomatic
BrS carriers (Fig. 2), and the ﬁrst 3 years was marked by increased
incidence of IS, after which the patients remain free of IS. The
incidence was highest (8.3%) in the ﬁrst year following implanta-
tion, increasing to 12% in the second before reaching the peak of
13.7% by the end of the third year, remaining static over the ensuing
7 years of follow-up. Sacher et al. [3] reported a different ﬁgure, but
the trend towards increased occurrence of IS among our cohort is
attenuated over time. Given the high rate of lead fracture in asso-
ciation with IS, one can hypothetically attribute the very high
occurrence of IS in the aerly post-implantation period to
procedure-related lead damage.
In contrast to previous studies [4,5,17], our study speciﬁed the
occurrence of IS in recipients of ICD for primary and secondary
prevention. This have provided an insight on the differential
burden of IS in asymptomatic and symptomatic patients with BrS, a
fact that previously unknown. Inappropriate shock is associated
with poor prognosis in ICD recipients [18,19], and the ﬁndings of
our study underscores the complexity associated with managing
asymptomatic patients with BrS [18,20]. This calls for a better
system of risk classiﬁcation to better guide the indications of ICD
implantation in this population of patients.
The mechanism underlying the delivery of IS in by an ICD in the
setting of primary and secondary prevention have not been eluci-
dated. Factors identiﬁed to be associated with increased risk of IS
include age less than 50 years. Younger patients have a higher
propensity for electrode failure due to physical activity, T wave
oversensing, and faster rates of atrial tachyarrhythmias [4e6,17].
However, these factors are equally distributed in our sample, and
thus cannot explain the somewhat higher susceptibility of
asymptomatic individuals. We speculate that younger asymptom-
atic individuals are more likely to engage in physical activities that
may uncover a hitherto concealed lead fracture to generate noise,
and consequently inappropriate therapies.
One issue that makes our ﬁndings rather intriguing is that the
risk of electrode fractures increases with time, especially in young
activemale patients [4,6]. It has been demonstrated that the hazard
of Sprint Fidelis lead fracture increases exponentially over timele cardioverter-deﬁbrillator shocks in Brugada syndrome: Pattern in
Journal (2016), http://dx.doi.org/10.1016/j.ipej.2016.10.010
Table 1
Baseline characteristics of the subjects.
Asymptomatic (n ¼ 18) Symptomatic (n ¼ 33) Total (n ¼ 51) p-value
Age at diagnosis (mean þ SD) 44.6 ± 12.5 48.1 ± 9.8 0.55
Malea 15(83.3) 30(90.9) 45(88.2) 0.18
Racea
White 16(88.9) 32(97) 48(94.1) 0.12
Black 0 1(3) 1(2) e
Asian 2(11.1) 0 2(3.9) e
Spontaneous type 1 ECGa 12(66.7) 28(84.8) 40(78.3) 0.16
AF before ICDa 3(16.7) 4(12.1) 7(13.7) 0.42
NSVT before ICDa 2(11.1) 7(21.2) 9(17.7) 0.67
Patients with EPSa 14(77.8) 18(54.6) 32(62.8) 0.22
SCN5Aa,b 0 1(3.0) 1(2.0) e
Family history of SCDa 9(50.0) 12(36.4) 21(41.2) 0.36
Quinidine therapya,c 4(22.2) 12(36.4) 16(31.4) 0.36
ECG ¼ Electrocardiogram, AF ¼ Atrial ﬁbrillation, NSVT ¼ Non-sustained ventricular tachycardia, EPS ¼ Electrophysiological study, SCN5A ¼ gene mutation encoding sodium
channel, SCD ¼ Sudden cardiac death.
a Expressed as number (%).
b Only 15 of the 51 patients had screening for SCN5A. mutation.
c Intention-to-treat analysis was considered to assess the effect of Quinidine therapy given for all indications (electrical storm or AF) after ICD.
Table 2
Implantable cardioverter-deﬁbrillator therapies and mechanisms of inappropriate shocks after 78 ± 46 months of follow-up.
Primary prevention (n ¼ 18) Secondary prevention (n ¼ 33) Total (n ¼ 51) p-valuea
Appropriate shocks 0(0) 11(33.3) 11(21.6) 0.006
Inappropriate shocksb
Lead malfunctionc 2(11.1) 2(11.1) 4(7.8) 0.522
Atrial ﬁbrillation 2(11.1) 0(0) 2(3.9) 0.0511
T-wave over-sensing 1(5.6) 0(0) 1(2) 0.707
Total with IS 5(27.8) 2(6.1) 7(13.7) 0.032
IS ¼ Inappropriate shock.
a p value for test of difference between proportions.
b Inappropriate shock presented by mechanism and total in the last row.
c Lead malfunction includes displacement, insulation erosion and conductor fracture.
Table 3
Rate of inappropriate shocks after ICD implantation.
Years Inappropriate shocks, n(%)
Primary prevention Secondary prevention Total
1 3(18.7) 1(3.1) 4(8.3)
2 4(23.5) 2(6.1) 6(12)
3 5(27.8) 2(6.1) 7(13.7)
4 5(27.8) 2(6.1) 7(13.7)
5 5(27.8) 2(6.1) 7(13.7)
10 5(27.8) 2(6.1) 7(13.7)
ICD¼Implantable cardioverter-deﬁbrillator.
A. Bonny et al. / Indian Pacing and Electrophysiology Journal xxx (2016) 1e64[21,22]. Moreover, the peculiarity of the patient's lead as depicted in
Fig. 2 is that insulation breach with low-voltage, non-physiological
signals are an uncommon pattern of failure with Sprint Fidelis
leads, which are prone to conductor fracture rather than insulation
abrasion [23]. Thus, the trend towards higher lead complication in
the early period after implantation in this population might not be
explained by the speciﬁc lead model. Why IS declined in the 4th
year onward, after the high incidence that characterizes the im-
mediate post-implantation period remained unexplained. Early
tracking of subclinical lead failure by means of lead integrity alerts
(LIA, Medtronic, Mineapolis, MN) or conventional impedance
monitoring may provide an insight [23].
Finally, the psychological state of ICD recipients is often
neglected [17,20]. In our study, 2 patients suffered severe depres-
sion and had been on medication. One of them received an ICD for
primary prevention, and did not experience any arrhythmic event
after 14 years of follow-up. In this regard, social impacts andPlease cite this article in press as: Bonny A, et al., Inappropriate implanta
primary and secondary prevention, Indian Pacing and Electrophysiologyconsequences for employment are important and should be
considered when dealing with young adults [20]. A reappraisal of
the beneﬁts and potential hazards of ICD insertions in the young
population of patients with Brugada syndrome will enable physi-
cians to have a more mutually informed and balanced dialogue
with their patients and relatives [18].
4.3. Study limitations
This is a retrospective study with a potential bias in the data
collection such as the adherence to quinidine, and the extent of
documentation of lead failures. Secondly, the number of patients is
small to conclusively interpret the results. It will be imperative to
carry out a similar study involving larger cohorts.
5. Conclusion
Brugada syndrome is characterized by young age of ICD carriers
with a high likelihood of experiencing inappropriate shocks. This
study showed that the highest risk of inappropriate therapy is in
the early post-implantation period, and mostly occurred in
asymptomatic younger patients receiving ICD for primary preven-
tion. In addition, the absence of arrhythmic events in our recipients
of ICD for primary prevention as well as reports of other registries
after a long term follow-up warrants a more careful evaluation of
these young and otherwise “healthy” individuals before implanting
an ICD. This approach can minimize the incidence of iatrogenic
depression and other complications. A study involving larger co-
horts of patient will be required to adjudicate our ﬁndings, and
possibly elucidate the mechanisms underlying the increased rate ofble cardioverter-deﬁbrillator shocks in Brugada syndrome: Pattern in
Journal (2016), http://dx.doi.org/10.1016/j.ipej.2016.10.010
Fig. 2. Kaplan-Meier curve of inappropriate shocks in BrS patients who underwent ICD implantation for primary and secondary prevention. Given the low prevalence of
Brugada syndrome in the general population, the difference between both groups was calculated using two-sided t-test a-level of 10%.
Fig. 3. Pace-sense failure related to inappropriate shock. A 54-year old asymptomatic female in whom an implantable cardioverter-deﬁbrillator was implanted have experienced
17 inappropriate shocks. Pace-sense insulation breach of a Sprint Fidelis lead (Medtronic, Mineapolis, MN) led to oversensing low-voltage nonphysiological signals.
A. Bonny et al. / Indian Pacing and Electrophysiology Journal xxx (2016) 1e6 5IS in this population.
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